Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented preclinical data for BI-456906, a novel long-acting glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, currently in phase II development in patients with obesity and nonalcoholic steatohepatitis (NASH).
A comprehensive nontargeted metabolomics analysis has revealed previously unknown classes of disease-linked metabolites in whole blood samples from dementia patients, which may have significant therapeutic implications for managing the untreatable common cognitive disorder.
A comprehensive nontargeted metabolomics analysis has revealed previously unknown classes of disease-linked metabolites in whole blood samples from dementia patients, which may have significant therapeutic implications for managing the untreatable common cognitive disorder.
